Viking Therapeutics Plummets 6% as VK2735 Trial Data Readout Looms
VKTX•Viking Therapeutics shares fell 6% Tuesday, marking their worst day since late March and worst week since November as investors await a pivotal maintenance dosing study readout. A 180-patient early-stage VK2735 trial, started in January, will report third-quarter results on injectable and oral regimens for sustained weight loss.
1. Stock Performance
Shares of Viking Therapeutics declined 6% on Tuesday, marking their worst daily drop since late March and positioning the stock for its worst week since November as traders await critical obesity drug data.
2. VK2735 Maintenance Dosing Study
Viking’s 180-patient early-stage trial, initiated in January, administers weekly injectable VK2735 for 19 weeks before switching to monthly injections, daily oral tablets, weekly oral tablets, or placebo to assess maintenance of weight loss and tolerability.
3. Retail Trader Sentiment
Retail discussion around Viking Therapeutics has surged, with sentiment shifting from bearish to neutral over the past 24 hours and message volume up 720% month-to-date as traders anticipate the maintenance trial readout.
4. Other Pipeline Catalysts
Viking plans pivotal late-stage trials for the VK2735 oral tablet formulation in Q4 2026 and expects initial safety and pharmacokinetic data from the VK3019 amylin receptor agonist study later this year.
